Savient files patent infringement lawsuit against Barr

By Lisa Kerner

Charlotte, N.C., Sept. 26 - Savient Pharmaceuticals, Inc. filed suit in the U.S. District Court for the District of New Jersey against Barr Laboratories, Inc., a wholly-owned subsidiary of Barr Pharmaceuticals, Inc., alleging infringement of five Savient U.S. patents related to Oxandrin (oxandrolone tablets, USP).

Oxandrin is an oral anabolic agent used to promote weight gain after weight loss following extensive surgery, chronic infection or severe trauma, according to a company news release.

Barr filed an abbreviated new drug application with the Food and Drug Administration to manufacture, use or sell 2.5 mg and 10 mg oxandrolone tablets prior to expiration of Savient's patents, prompting the lawsuit filing by the East Brunswick, N.J., specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.